163 related articles for article (PubMed ID: 38201278)
41. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.
Kemper K; Krijgsman O; Cornelissen-Steijger P; Shahrabi A; Weeber F; Song JY; Kuilman T; Vis DJ; Wessels LF; Voest EE; Schumacher TN; Blank CU; Adams DJ; Haanen JB; Peeper DS
EMBO Mol Med; 2015 Sep; 7(9):1104-18. PubMed ID: 26105199
[TBL] [Abstract][Full Text] [Related]
42. SOX10-MITF pathway activity in melanoma cells.
Tudrej KB; Czepielewska E; Kozłowska-Wojciechowska M
Arch Med Sci; 2017 Oct; 13(6):1493-1503. PubMed ID: 29181082
[TBL] [Abstract][Full Text] [Related]
43. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
44. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Capparelli C; Purwin TJ; Glasheen M; Caksa S; Tiago M; Wilski N; Pomante D; Rosenbaum S; Nguyen MQ; Cai W; Franco-Barraza J; Zheng R; Kumar G; Chervoneva I; Shimada A; Rebecca VW; Snook AE; Hookim K; Xu X; Cukierman E; Herlyn M; Aplin AE
Nat Commun; 2022 Mar; 13(1):1381. PubMed ID: 35296667
[TBL] [Abstract][Full Text] [Related]
45. Lipocalin-2 regulates the expression of interferon-stimulated genes and the susceptibility of prostate cancer cells to oncolytic virus infection.
Barer L; Schröder SK; Weiskirchen R; Bacharach E; Ehrlich M
Eur J Cell Biol; 2023 Jun; 102(2):151328. PubMed ID: 37321037
[TBL] [Abstract][Full Text] [Related]
46. Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔPK oncolytic activity in melanoma.
Colunga A; Bollino D; Schech A; Aurelian L
Gene Ther; 2014 Apr; 21(4):371-8. PubMed ID: 24553345
[TBL] [Abstract][Full Text] [Related]
47. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
[TBL] [Abstract][Full Text] [Related]
48. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.
García M; Moreno R; Gil-Martin M; Cascallò M; de Olza MO; Cuadra C; Piulats JM; Navarro V; Domenech M; Alemany R; Salazar R
Hum Gene Ther; 2019 Mar; 30(3):352-364. PubMed ID: 30234393
[TBL] [Abstract][Full Text] [Related]
49. Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma.
Numpadit S; Ito C; Nakaya T; Hagiwara K
Med Oncol; 2023 Apr; 40(5):138. PubMed ID: 37022566
[TBL] [Abstract][Full Text] [Related]
50. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
51. Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.
Schipper H; Alla V; Meier C; Nettelbeck DM; Herchenröder O; Pützer BM
Oncotarget; 2014 Aug; 5(15):5893-907. PubMed ID: 25071017
[TBL] [Abstract][Full Text] [Related]
52. FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor.
Sun Q; Novak D; Hüser L; Poelchen J; Wu H; Granados K; Federico A; Liu K; Steinfass T; Vierthaler M; Umansky V; Utikal J
Int J Cancer; 2021 Aug; 149(3):657-674. PubMed ID: 33837564
[TBL] [Abstract][Full Text] [Related]
53. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
54. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
[TBL] [Abstract][Full Text] [Related]
55. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
56. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
57. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Beck D; Niessner H; Smalley KS; Flaherty K; Paraiso KH; Busch C; Sinnberg T; Vasseur S; Iovanna JL; Drießen S; Stork B; Wesselborg S; Schaller M; Biedermann T; Bauer J; Lasithiotakis K; Weide B; Eberle J; Schittek B; Schadendorf D; Garbe C; Kulms D; Meier F
Sci Signal; 2013 Jan; 6(260):ra7. PubMed ID: 23362240
[TBL] [Abstract][Full Text] [Related]
58. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Bommareddy PK; Patel A; Hossain S; Kaufman HL
Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
[TBL] [Abstract][Full Text] [Related]
59. Naturally Occurring and Engineered Alphaviruses Sensitive to Double-Stranded-RNA-Activated Protein Kinase Show Restricted Translation in Mammalian Cells, Increased Sensitivity to Interferon, and Marked Oncotropism.
Toribio R; Díaz-López I; Berlanga JJ; Molina-Jiménez F; Majano P; Ventoso I
J Virol; 2020 Jan; 94(3):. PubMed ID: 31723025
[TBL] [Abstract][Full Text] [Related]
60. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.
Nguyen TT; Ramsay L; Ahanfeshar-Adams M; Lajoie M; Schadendorf D; Alain T; Watson IR
Clin Cancer Res; 2021 Jun; 27(12):3432-3442. PubMed ID: 33593882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]